Insider transactions

Robert Carey

CIK 1602064 · EVP, Chief Business Officer · last filed 2025-11-07

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure
$30.4K
Companies
4
Total Filings
71
Lifetime Open-Market Net
$8.91M

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

XAIR price and trades

Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.

Shares held

Shares owned after each reported transaction on this company (direct holdings as reported).

Open-market buying and selling

by month

Dollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.

Exposure by company

latest
OfficerDirector10% owner* stale (no filing in 3 yrs)

Most recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.

Filer Profile

Reported Address
SANGAMO THERAPEUTICS, INC.
501 CANAL BLVD.
RICHMOND, CA 94084
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
XAIR Director 13,859 $2.19 $30.4K $9.42M 36 2025-11-07
SANGAMO THERAPEUTICS, INC (SGMO) Delisted Director 99,600 $0.18 $17.7K $0 11 2025-06-16
Horizon Therapeutics Public Ltd Co (HZNP) Delisted EVP, Chief Business Officer 266,358 $116.30 $30.98M -$509.8K 17 2019-03-25
ARGOS THERAPEUTICS INC (ARGS) Delisted Director 410 — — $0 6 2017-01-20

Recent Filings · Page 5 of 8

71 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2020-06-03 SANGAMO THERAPEUTICS, INC (SGMO) Delisted Grant (A) +10,000 $0 EDGAR
2020-05-20 SANGAMO THERAPEUTICS, INC (SGMO) Delisted Grant (A) +2,500 $0 EDGAR
2019-11-22 XAIR Buy (P) +19,418 $100.0K EDGAR
2019-06-12 SANGAMO THERAPEUTICS, INC (SGMO) Delisted Grant (A) +2,500 $0 EDGAR
2019-03-25 Horizon Therapeutics Public Ltd Co (HZNP) Delisted Mixed +17,267 -$368.6K EDGAR
2019-02-22 Horizon Therapeutics Public Ltd Co (HZNP) Delisted Mixed +40,311 -$690.7K EDGAR
2019-02-22 — Grant (A) — $0
2019-01-08 Horizon Therapeutics Public Ltd Co (HZNP) Delisted Mixed +36,276 -$599.9K EDGAR
2018-06-12 SANGAMO THERAPEUTICS, INC (SGMO) Delisted Grant (A) +2,500 $0 EDGAR
2018-05-07 Horizon Therapeutics Public Ltd Co (HZNP) Delisted Grant (A) — $0 EDGAR
Showing 41–50 of 71
Page 5 of 8
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.